In addition, treatment with SCFAs has been shown to prevent vascular dysfunction and elevated blood pressure (BP) in mice with systemic lupus erythematosus (SLE) induced by imiquimod (IMQ) activation of TLR7. Here, TLR7 is linked to systemic lupus erythematosus.